- $2.43bn
- $2.34bn
- $1.76bn
- 78
- 96
- 75
- 97
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 20-F | 20-F | 20-F | 20-F | 20-F |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 1,767 | 1,690 | 2,257 | 1,836 | 1,760 |
Cost of Revenue | |||||
Gross Profit | 1,438 | 1,388 | 1,853 | 1,436 | 1,386 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 1,419 | 1,395 | 1,666 | 1,427 | 1,311 |
Operating Profit | 348 | 295 | 591 | 409 | 449 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | 602 | 376 | 551 | 128 | 503 |
Provision for Income Taxes | |||||
Net Income After Taxes | 493 | 315 | 412 | 97.8 | 357 |
Minority Interest | |||||
Net Income Before Extraordinary Items | |||||
Net Income | 495 | 313 | 428 | 85.6 | 343 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Dilution Adjustment | |||||
Diluted Net Income | 495 | 313 | 428 | 85.6 | 343 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | 3.09 | 2.16 | 2.21 | 0.624 | 1.5 |
Special Dividends per Share |